AstraZeneca PLC vs Abbvie Inc.
AZN vs ABBV — side-by-side comparison from reported financials. AZN leads 6, ABBV leads 6 of 12 comparable metrics.
AstraZeneca PLC
AZN · Healthcare
$159.20+0.26%Solid
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | AZN | ABBV |
|---|---|---|
| Price | $159.20 | $276.43 |
| Market cap | $247B | $488B |
| Revenue (TTM) | $58.7B | $64.4B |
| Revenue growth | +9.8% | +1.8% |
| Net margin | 17.4% | 9.8% |
| Free cash flow | $10.7B | $18.2B |
| Net cash (debt) | ($27.4B) | ($56.2B) |
| 1-year price return | -6.4% | +19.8% |
| P/E | 23.4 | 77.4 |
| P/E vs own history (cheap-side %) | 65% | 23% |
| Dividend yield | 2.01% | 2.45% |
| Return on equity | 22% | 96% |
| Altman Z-score | 2.16 | 2.33 |
| CV checks passed | 11 of 11 | 9 of 11 |
| Employees | 96,100 | 57,000 |
Full résumé-style profiles: AZN CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.